Evidence map›Paper›PMID 41069245›Full record

ArticleJournal of gastroenterology and hepatology2025

IBD 2024: Charting a New Course in IBD Proceedings of the Takeda Symposium 22-23 November 2024 W Hotel, Brisbane, Queensland, Australia.

Uma Mahadevan, Vipul Jairath, Jakob Begun, Aviv Pudipeddi, Mayur Garg, Peter De Cruz, Christopher F D Li Wai Suen, Matthew C Choy, Danny Con, Rose Vaughan and 6 more

Abstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Uma MahadevanDivision of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
Vipul JairathDepartment of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada.ORCID https://orcid.org/0000-0002-1092-0033
Jakob BegunDepartment of Gastroenterology, Mater Hospital Brisbane, South Brisbane, Australia.ORCID https://orcid.org/0000-0001-5256-7672
Aviv PudipeddiDepartment of Gastroenterology and Liver Services, Concord Repatriation General Hospital, Concord, NSW, Australia.ORCID https://orcid.org/0000-0002-3664-2246
Mayur GargNorthern Health, Melbourne, Australia.
Peter De CruzDepartment of Medicine, Austin Health-The University of Melbourne, Melbourne, Australia.
Christopher F D Li Wai SuenDepartment of Medicine, Austin Health-The University of Melbourne, Melbourne, Australia.
Matthew C ChoyDepartment of Medicine, Austin Health-The University of Melbourne, Melbourne, Australia.
Danny ConDepartment of Medicine, Austin Health-The University of Melbourne, Melbourne, Australia.ORCID https://orcid.org/0000-0002-4983-6103
Rose VaughanDepartment of Gastroenterology, Royal Melbourne Hospital, Australia.
John D ChetwoodConcord Repatriation General Hospital, Sydney, NSW, Australia.ORCID https://orcid.org/0000-0002-8947-9817
David A ClarkFaculty of Medicine, University of Queensland, Brisbane, Australia.
Craig HaiferDepartment of Gastroenterology, St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.
Miles P SparrowDepartment of Gastroenterology, Alfred Health, Melbourne, Australia.
Rupert LeongConcord Hospital, Sydney, NSW, Australia.ORCID https://orcid.org/0000-0001-5944-3488
Réme MountifieldFlinders University of South Australia, Southern Adelaide Local Health Network, Flinders Medical Centre, Bedford Park, SA, Australia.

Funding

Takeda Pharmaceuticals Pty Ltd, Sydney, Australia
6 · The paper itself

Abstract

The symposium IBD 2024: Charting a New Course in IBD was held in Brisbane, Australia, in November 2024. This was the fifth such meeting for the Australian inflammatory bowel disease (IBD) healthcare community. This symposium provided an overview of current and emerging management strategies for ulcerative colitis (UC) and Crohn's disease (CD). Key topic areas covered included the importance of treating to a minimum of endoscopic remission; important considerations for treatment choice, treatment switch, and treatment de-escalation; treatment during pregnancy; and emerging therapeutic options. This supplement provides a detailed summary of each of the symposium presentations, as well as key take-home messages.

Indexed as

Colitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesAustraliaFemaleHumansPregnancyQueenslandRemission InductionCrohn's diseaseemerging therapeutic optionsendoscopic remissionIBDulcerative colitis

Identifiers

PMID41069245
PMCPMC12511924

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.